Observes semaglutide use in adults with obesity through digital weight care in Australia
Studies how adults with obesity use semaglutide within a digital weight loss program.
Plain-language title generated from the registry record
Registry title: Semaglutide Health Outcomes and Patient Adherence in Australia
Key facts
- Where
- Sydney, AustraliaSee the site
Where in Australia
- SydneySydney, AustraliaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Novo Nordisk A/S
- Trial code
- NCT07881770
- Record updated
- 19 October 2026
- Original description
This observational study aims to generate real-world evidence on the use of semaglutide in adults with overweight or obesity receiving care through a digital weight loss service (DWLS) programme in Australia. The study will evaluate treatment patterns, adherence, quality of life, safety, and other health outcomes associated with semaglutide use in routine clinical practice. Information will be collected from data generated during standard clinical care, and no study-specific treatment or procedures will be required.Read full original descriptionShow less
Semaglutide Health Outcomes and Patient Adherence on Digital Health Platforms in Australia (SHAPED-AU)
This observational study aims to generate real-world evidence on the use of semaglutide in adults with overweight or obesity receiving care through a digital weight loss service (DWLS) programme in Australia. The study will evaluate treatment patterns, adherence, quality of life, safety, and other health outcomes associated with semaglutide use in routine clinical practice. Information will be collected from data generated during standard clinical care, and no study-specific treatment or procedures will be required.
Inclusion: Willing and able to provide informed consent; Greater than or equal to (>=) 18 years of age at time of informed consent; Body Mass Index (BMI) >= 27 kg/m2 and have >= 1 excess weight-related comorbidity OR BMI >= 30 kg/m2; Eligible to be prescribed semaglutide for the management of overweight or obesity; Have provided at least one weight measurement within 30 days of index date; Enrolled in existing Eucalyptus DWLS programme.
Exclusion: Previous reported use of GLP-1 RA in the 3-month period before index date; Are currently taking another obesity medication i.e. medication indicated for weight management treatment; Any prior irreversible bariatric surgery for weight management; Presence of a documented refusal to participate in research.